Eosinophilic granulomatosis with polyangiitis
ORPHA:183DiseaseNot applicableAdolescent, Adult, Elderly
Фенотипы (HPO)66
Очень частый (80–99%)12
HP:0000246Sinusitis
HP:0000979Purpura
HP:0001025Urticaria
HP:0001824Weight loss
HP:0001880Eosinophilia
HP:0002099Asthma
HP:0002113Pulmonary infiltrates
HP:0002633Vasculitis
HP:0002960Autoimmunity
HP:0007009Central nervous system degeneration
HP:0009830Peripheral neuropathy
HP:0012649Increased inflammatory response
Частый (30–79%)24
HP:0000790Hematuria
HP:0000822Hypertension
HP:0000988Skin rash
HP:0001053Hypopigmented skin patches
HP:0001288Gait disturbance
HP:0001639Hypertrophic cardiomyopathy
HP:0001697Abnormal pericardium morphology
HP:0001970Tubulointerstitial nephritis
HP:0002015Dysphagia
HP:0002017Nausea and vomiting
HP:0002027Abdominal pain
HP:0002103Abnormality of the pleura
HP:0002829Arthralgia
HP:0002923Rheumatoid factor positive
HP:0003212Increased circulating IgE level
HP:0004936Venous thrombosis
HP:0006536Airway obstruction
HP:0012378Fatigue
HP:0032018Multiple mononeuropathy
HP:0032071Eosinophilic pneumonia
HP:0032230Cytoplasmic antineutrophil antibody positivity
HP:0033557Anti-proteinase 3 antibody positivity
HP:0033559Anti-myeloperoxidase antibody positivity
HP:0034104Anti-neutrophil elastase antibody positivity
Периодический (5–29%)30
HP:0000083Renal insufficiency
HP:0000093Proteinuria
HP:0000965Cutis marmorata
HP:0001063Acrocyanosis
HP:0001369Arthritis
HP:0001482Subcutaneous nodule
HP:0001635Congestive heart failure
HP:0001658Myocardial infarction
HP:0001945Fever
HP:0002020Gastroesophageal reflux
HP:0002024Malabsorption
HP:0002093Respiratory insufficiency
HP:0002105Hemoptysis
HP:0002202Pleural effusion
HP:0002326Transient ischemic attack
HP:0003326Myalgia
HP:0004374Hemiplegia/hemiparesis
HP:0005214Intestinal obstruction
HP:0006535Recurrent intrapulmonary hemorrhage
HP:0006824Cranial nerve paralysis
HP:0008653Crescentic glomerulonephritis
HP:0012735Cough
HP:0012819Myocarditis
HP:0032064Gastrointestinal eosinophilia
HP:0100582Nasal polyposis
HP:0100584Endocarditis
HP:0100614Myositis
HP:0100820Glomerulopathy
HP:0200034Papule
HP:6000070Cutaneous granuloma
Эпидемиология19
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 1.56 | Europe | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.09 | Sweden | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.13 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.4 | Sweden | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.09 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.3 | Norway | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.09 | Spain | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.23 | Australia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.18 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.5 | Worldwide | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.05 | Norway | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.11 | Germany | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.13 | Lithuania | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.12 | France | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.06 | Turkey | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.014 | Peru | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.4 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.78 | Japan | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.4 | United States | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)